Day 1- Wednesday September 10th - EST (Eastern Time, UTC-05:00
Developing a novel reactor system that co-immobilizes T7 polymerase and DNA templates, enabling efficient, high-purity mRNA synthesis with reduced dsRNA impurities
Enabling scalable and cost-effective, streamlined mRNA therapeutics manufacturing
- Craig Martin - Professor, University of Massachusetts Amherst
- Adoption of RNA as a vaccine and therapeutic modality highlights the need for robust, cost-effective production and improved targeted delivery.
- Look into how a rapid and efficient manufacturing process that combined with in-process analytics enable achieving IVT yields up to 25 g of RNA per L and attaining 80-100 % of RNA recovery after purification.
- Discover how innovating mRNA-LNP formulation supported by in-process analytics can lead to the generation of mRNA LNPs that have expanded extrahepatic biodistribution, improved drug delivery and cellular targeting.
- Tomas Kostelec - Manager of Segment Technology for Advanced Therapies, Sartorius
Key process adaptations and challenges in scaling individualized cancer vaccines
Strategies to streamline and automate bespoke mRNA vaccine workflows for clinical use.
- Single-use biochips eliminate patient-to-patient risk of cross-contamination
- Personalized manufacturing and release process with NMU-Symphony™
- From RNA-design to patient-injectable vials in 3 weeks
- Babak Sanii - Director of Biochip R&D, Nutcracker Therapeutics
Implementing green chemistry and energy-efficient processes to reduce the environmental footprint of mRNA vaccine production.
Exploring sustainable sourcing of raw materials and waste reduction strategies
Discussing how AI-driven automation can streamline and optimize the mRNA vaccine manufacturing process, improving scalability, reducing production time, and ensuring consistent quality for improved global access.